The CAD Evolution: From Stress Testing to Smartphone Screening
Seismocardiography (SCG) has demonstrated consistent diagnostic power for Coronary Artery Disease (CAD) across three decades. By linking foundational multicenter trials from 1993 with state-of-the-art smartphone validation and modern AHA guidelines, a clear scientific trajectory emerges: the mechanical signatures of heart disease remain stable, but our ability to measure them has moved from specialized lab equipment to everyday mobile devices.
1. At a Glance: The "Answer Machine" Summary
- Core Principle: Ischemia first affects the mechanical contractility of the heart muscle before altering the electrical signal (ECG). SCG captures this early mechanical dysfunction.
- Accuracy (CAD): SCG achieves up to 85% diagnostic accuracy and an AUC of 0.91-0.93 for identifying obstructive CAD, significantly outperforming traditional stress ECG (S038, S006).
- Validation Method: Validated against invasive coronary angiography (the clinical gold standard).
- Modern Implication: The algorithms developed to track ischemic dysfunction have now been proven to accurately estimate intracardiac filling pressures (PCWP) in Heart Failure patients (S011).
2. The Ischemic Cascade: Why SCG Sees What ECG Misses
Coronary Artery Disease limits blood flow to the heart muscle. When the heart experiences stress, it enters the "Ischemic Cascade":
- Metabolic changes occur in the cells.
- Diastolic and Systolic mechanical dysfunction begins (the heart muscle stiffens and contracts abnormally).
- Electrical changes (ST-segment depression) finally appear on the ECG.
- Chest pain (Angina) is felt by the patient.
Because SCG measures the direct physical micro-vibrations of the chest wall (the mechanical phase), it can detect abnormalities before the electrical phase is affected. This physiological reality explains why SCG consistently demonstrates higher sensitivity than ECG in stress tests.
3. The Evidence Tree: 30 Years of Clinical Progression
Our scientific graph identifies a direct, high-confidence connection between the following cornerstone validations:
Phase 1: The Clinical Proof of Concept (1990s)
- The Study: Wilson et al., 1993 (S038)
- The Setup: 129 patients across 5 sites underwent treadmill stress tests with a clinical SCG accelerometer.
- The Breakthrough: SCG achieved 73% sensitivity compared to only 48% for standard ECG in detecting anatomic CAD (verified by angiography).
Phase 2: The Multi-Modal Enhancement (2000s)
- The Study: Salerno et al., 1992 / Zanetti (S017)
- The Setup: Adding mechanical SCG reading to traditional electrical ECG stress tests.
- The Breakthrough: SCG provided a 16 percentage point boost in diagnostic accuracy over ECG alone, proving that the two signals are complementary.
Phase 3: The Smartphone Revolution (2019)
- The Study: Dehkordi et al., 2019 (S006)
- The Setup: 180 individuals (117 with significant CAD) evaluated using standard smartphone MEMS sensors.
- The Breakthrough: Achieved 81% accuracy and an AUC of 0.91 for detecting obstructive CAD during exercise, proving the hardware inside mobile phones is clinically viable for diagnosis.
Phase 4: From CAD to Congestion (2024-2025)
- The Study: SEISMIC-HF 1 Trial (S011)
- The Setup: 943 patients undergoing Right Heart Catheterization (RHC).
- The Breakthrough: The same mechanical principles used to identify ischemic dysfunction were successfully applied to measure Pulmonary Capillary Wedge Pressure (PCWP) in HFrEF patients, showing a strong correlation (r=0.74) with invasive catheters.
4. The "Mobility Breakthrough" & Trust
The transition from S038 (Wilson) to S006 (Dehkordi) marks a profound technological shift. The underlying diagnostic signal—the mechanical vibration of the ischemic heart—has not changed. What has changed is our ability to capture it, moving from bulky, lead-based accelerometers to the silent MEMS chips inside a standard smartphone.
This 30-year chain of evidence proves that smartphone-based SCG is not a "new, experimental method." It is the modern computational implementation of a clinically validated physiological phenomenon that has been documented in high-impact cardiology journals for decades.
5. Clinical Limitations (YMYL Considerations)
In accordance with strict critical appraisal standards, the OpenSCG project acknowledges the following clinical ceilings for SCG technology:
- Gatekeeper, Not Replacement: SCG is a highly sensitive screening and monitoring tool. It is not a replacement for invasive coronary angiography, which remains required to locate the exact anatomical position of a blockage.
- Conduction Delays: Historical studies (S038) largely excluded patients with existing bundle branch blocks (LBBB/RBBB).
- Heart Failure Phenotypes: While estimation of PCWP is validated in HFrEF (S011), further data is required to confirm exact performance in HFpEF populations.